$Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.$

Polatuzumab vedotin combined with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma: A systematic review protocol.

<h4>Background</h4>Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma subtype with a significant relapse rate and poor prognosis in relapsed/refractory (R/R) patients. Polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) has demonstrated p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mohammadreza Eslami, Mahdi Mehrabi, Mehrdad Payandeh, Fakhredin Saba
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0308247
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
by: Margaret Hux, et al.
Published: (2016-10-01)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01)

Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model
by: Lin Yang, et al.
Published: (2025-01-01)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
by: Hung-Bo Wu, et al.
Published: (2013-01-01)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
by: R. Palmieri, et al.
Published: (2019-01-01)

Bendamustine Associated with Irreversible Ascending Paralysis
by: Ashraf Alhafez, et al.
Published: (2013-01-01)

Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin
by: Federico Meconi, et al.
Published: (2019-01-01)

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients
by: Evgeny Klyuchnikov, et al.
Published: (2011-01-01)

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
by: Narendranath Epperla, et al.
Published: (2025-01-01)

Systemic Relapse in a Young Adult Patient with Primary CNS Diffuse Large B-Cell Lymphoma
by: Adam Khorasanchi, et al.
Published: (2022-01-01)

Therapeutic potential of brentuximab vedotin in breast cancer and lymphoma via targeted apoptosis and gene regulation
by: Abeer Ezzat, et al.
Published: (2025-01-01)

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
by: Elise A. Chong, et al.
Published: (2025-02-01)

Remission Achieved in Refractory Advanced Takayasu Arteritis Using Rituximab
by: D. Ernst, et al.
Published: (2012-01-01)

Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare
by: Emmanuel Ribeiro, et al.
Published: (2009-01-01)

Large-Cell Neuroendocrine Cancer of the Colon following Rituximab-Based Lymphoma Treatment
by: Hugh J Freeman, et al.
Published: (2012-01-01)

PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
by: Peng Sun, et al.
Published: (2025-02-01)

Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma
by: Rui Zhang, et al.
Published: (2025-01-01)

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study
by: Mario Petrini, et al.
Published: (2022-01-01)

A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy
by: Rajiv M. Mallipudi, et al.
Published: (2019-01-01)

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
by: Jessy Xinyi Han, et al.
Published: (2025-02-01)

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
by: Rossana Di Staso, et al.
Published: (2024-11-01)

Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma
by: Takuya Suyama, et al.
Published: (2024-01-01)

Relapse of Diffuse Large B‐Cell Lymphoma as Painless Masses in the Abdominal Wall Muscles: A Rare Case Report
by: Somar Mansour, et al.
Published: (2025-01-01)

Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada
by: Jenna Shaw, et al.
Published: (2024-12-01)

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
by: Claudio Fozza, et al.
Published: (2011-01-01)

Long-term survival and clinical implications of allogeneic stem cell transplantation in relapse/refractory lymphoma: A 20-year Singapore experience
by: Wei Sheng Joshua Loke, et al.
Published: (2025-01-01)

Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structural equation model (SEM) analysis 2012-2022.
by: Saaya Tsutsué, et al.
Published: (2025-01-01)

Matching plus regression adjustment for the estimation of the average treatment effect on survival outcomes: a case study with mosunetuzumab in relapsed/refractory follicular lymphoma
by: Danilo Di Maio, et al.
Published: (2025-02-01)

Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis
by: Fanqiao Meng, et al.
Published: (2025-01-01)

Steroid Refractory Autoimmune Haemolytic Anaemia Secondary to Sarcoidosis Successfully Treated with Rituximab and Mycophenolate Mofetil
by: Sarah Green, et al.
Published: (2016-01-01)

Efficacy of low-dose rituximab versus immunosuppressants in refractory orbital inflammatory pseudotumors with intracranial extension
by: Yuyu Li, et al.
Published: (2025-01-01)

Refractory and relapsing forms of <i>Clostridium difficile</i>-associated colitis
by: A. A. Sheptulin
Published: (2011-03-01)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
by: Manu R. Pandey, et al.
Published: (2017-01-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

Clonally Related Plasmablastic Lymphoma Simultaneously Occurring with Diffuse Large B-Cell Lymphoma
by: Norisato Hashimoto, et al.
Published: (2020-01-01)

Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
by: Ayotola Fatola, et al.
Published: (2025-01-01)

Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma
by: Toshiki Kijima, et al.
Published: (2025-01-01)

New bispecific antibodies in diffuse large B-cell lymphoma
by: Adrian G. Minson, et al.
Published: (2025-02-01)

Diffuse Large B Cell Lymphoma Mimicking Granulomatosis with Polyangiitis
by: Mohammad E. Naffaa, et al.
Published: (2016-01-01)

Epiphyseal Primary Diffuse Large B-Cell Lymphoma of Bone
by: Shachar Kenan, et al.
Published: (2018-01-01)